Acrodermatitis chronica atrophicans natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{ACA}} | {{ACA}} | ||
==Natural History== | ==Natural History== | ||
The course of ACA is long-standing, from a few to several years, and it leads to extensive [[atrophy]] of the skin and, in some patients, to the limitation of upper and lower limb [[joint]] mobility. | The course of ACA is long-standing, from a few to several years, and it leads to extensive [[atrophy]] of the skin and, in some patients, to the limitation of upper and lower limb [[joint]] mobility. | ||
Line 14: | Line 13: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Needs overview]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] |
Revision as of 17:12, 3 December 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Acrodermatitis chronica atrophicans Microchapters |
Differentiating Acrodermatitis chronica atrophicans from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Acrodermatitis chronica atrophicans natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans natural history, complications and prognosis |
FDA on Acrodermatitis chronica atrophicans natural history, complications and prognosis |
CDC on Acrodermatitis chronica atrophicans natural history, complications and prognosis |
Acrodermatitis chronica atrophicans natural history, complications and prognosis in the news |
Blogs on Acrodermatitis chronica atrophicans natural history, complications and prognosis |
Natural History
The course of ACA is long-standing, from a few to several years, and it leads to extensive atrophy of the skin and, in some patients, to the limitation of upper and lower limb joint mobility.
Prognosis
The outlook is good if the acute inflammatory stage of ACA is treated adequately. The therapeutic outcome is difficult to assess in patients with the chronic atrophic phase, in which many changes are only partially reversible.